Category: Business

PLANO, TX / ACCESS Newswire / July 14, 2025 / Plano Overhead Garage Door, the most awarded garage door company in the Dallas-Fort Worth area, has once again earned the 2025 Consumer Choice Award in the Garage and Overhead Door category – marking an outstanding 14 consecutive years of recognition for trusted service and superior workmanship. This milestone highlights nearly five decades of dedication to fair pricing, community connection, and exceptional customer care for homeowners throughout North Texas.

Family-owned and operated since 1977, Plano Overhead Garage Door has built its reputation one household at a time, combining professional expertise with a genuine commitment to honesty and convenience. From emergency repairs to complete garage door installations, the company remains the first call for thousands of local families who value quality they can rely on.

Same-Day Service with a Personal Touch
One hallmark of Plano Overhead Garage Door’s success is their approach to customer service. Every homeowner receives a free estimate, a same-day appointment with a guaranteed 30-minute arrival window, and a personal text introducing the certified service professional en route – complete with a photo, fun facts, and a live link to track their arrival in real time. It’s thoughtful, transparent service that puts homeowners at ease.

“Winning the Consumer Choice Award for the 14th consecutive year means so much to our team because it reflects what truly matters – the trust and satisfaction of our community,” said the Plano Overhead Garage Door team. “We’re proud to keep raising the bar for what homeowners can expect from a garage door company, year after year.”

Certified Professionals, Quality You Can See
Plano Overhead Garage Door focuses exclusively on residential garage door repairs, replacements, opener upgrades, and preventative maintenance. With a showroom conveniently located off Highway 75 in Plano, customers can compare doors, touch sample panels, and see opener demonstrations before making a decision – a level of hands-on service rare in today’s online-first world.

All technicians are certified and thoroughly trained to handle everything from broken spring replacements to installing insulated doors that improve energy efficiency and enhance curb appeal. Backed by robust warranties, each job is done right the first time – with no surprise fees and no sales pressure.

Clear Pricing, No Gimmicks
Plano Overhead Garage Door has stayed true to the values it was founded on nearly 50 years ago: fair, upfront pricing and clear communication. Free estimates ensure no hidden costs, and the company’s warranties offer industry-leading protection that homeowners can trust long after the installation is complete.

This straightforward approach, combined with consistent five-star reviews, has earned the company a reputation as a trusted local partner for families across Plano, Collin County, and beyond.

Protecting Homes and Giving Back
As a family business, Plano Overhead Garage Door believes in giving back to the communities that have supported them for generations. The team participates in local events, supports neighborhood associations, and donates services when neighbors are in need – reinforcing their role not just as a service provider, but as a dependable local presence.

Building on a Legacy of Excellence
As they celebrate this 14th consecutive Consumer Choice Award, Plano Overhead Garage Door remains focused on continuous improvement. The company plans to grow its team of certified professionals, introduce new product lines featuring the latest smart-home and energy-saving technologies, and continue refining the customer experience with even more flexible scheduling and personalized service.

No matter how they grow, the company stays rooted in the same values of trust, integrity, and quality workmanship that have defined it for nearly five decades – and that have earned Plano Overhead Garage Door its remarkable track record of community recognition.

Visit the Showroom or Book a Free Estimate
Homeowners are welcome to visit the Plano showroom on Highway 75 to explore doors and openers in person, speak with knowledgeable staff, and get personalized recommendations. To learn more, request a free quote, or schedule same-day service, CLICK HERE or visit www.planooverhead.com.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that the design of the adaptive clinical trial protocol for the treatment of MPox Virus Clade Ia and Ib infections and disease is nearly complete.

The adaptive clinical trial is designed to provide information on three important aspects in a single, compact clinical trial:

1. safe and effective dosing regimen in patients,

2. safety and tolerability of the drug in patients, and

3. antiviral effectiveness of the drug in patients.

The overall clinical trial will enroll approximately 80 patients.

“This is an important milestone towards filing of the clinical trial application and starting the clinical trial,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, “Our CRO and the Principal Investigator have created a marvelous design that is both frugal and efficient while providing all of the information necessary for understanding the safety and effectiveness of NV-387 for treating MPox disease.”

Currently there is no drug approved for the treatment of MPox disease that is actually effective for treating the disease.

NV-387, if it shows effectiveness, will be the very first drug that has shown effectiveness in human clinical trial of an orthopoxvirus.

If NV-387 is found to be effective in this Phase II clinical trial, the Company intends to continue further development of NV-387 for treatment of orthopoxvirus infections under a US FDA IND towards studies as needed for regulatory approval of NV-387 for the treatment of MPox as well as Smallpox indications. The Company intends to obtain regulatory approval in the African Region as well, which is likely to arrive before a US approval, and also seek approvals in the European Union and other countries and regions.

MPox is an Orphan disease in the USA and treatment of MPox by NV-387 is eligible for Orphan Drug Designation by the US FDA with attendant benefits.

Smallpox is a bioterrorism agent of concern in the USA as well as across the world and is an important revenue opportunity for the Company. Tecovirimat sales to the US Government alone have netted SIGA, the drug holder, over $600 million through December 31, 2024, according to SIGA’s annual report to the SEC ^[1] .

The adaptive, randomized, SOC controlled clinical trial will proceed in two parts:

In Phase IIa part, an oral dose of the drug NV-387 given twice daily initially for six days will be compared with the standard of care (SOC) at the hospital for treatment of MPox disease. Patients will be sequestered in the hospital and will be evaluated daily for clinical drug safety and tolerability parameters, and clinical MPox disease evaluation parameters. Additionally, lab evaluations including clinical blood chemistry, CBC, cytokines, urinalysis, ECG, X-rays when necessary, and virological assays will be conducted every 3 days. Based on the results, the Principal Investigator will determine whether additional days of drug dosing can be well tolerated and can improve on effectiveness. If so, the patients will continue to receive same dosing for six more days with same evaluations. The patients will be followed until full resolution of the MPox disease.

There will be two arms in this Phase IIa: The New Treatment Arm of 10 patients with NV-387 dosing plus SOC and the control SOC Arm of 10 patients. The dosing regimen for Phase IIb will be determined on the basis of Phase IIa results.

In the Phase IIb part, the clinical trial will be in a 2:1 randomized patients base with approximately 40 subjects in the New Treatment Arm and 20 patients in the SOC Arm. Evaluations will be similar to those in Phase IIa, with more emphasis given to specific points that may have come up in Phase IIa regarding safety, tolerability, as well as efficacy.

The Phase IIa will be conducted at a single site in Democratic Republic of Congo (DRC). Phase IIb may be expanded to include additional sites within DRC as well as other countries experiencing severe MPox outbreak in the African Region.

The “NV-387 Oral Gummies” drug product formulation will be employed in the Phase II. This is a soft solid formulation that is designed to stick in the oral cavity and dissolve naturally over time, with no solid object (pill or capsule) swallowing necessary. This is important for MPox because MPox causes lesions on mucosal surfaces that make swallowing painful and difficult. MPox is primarily known for the explicit characteristic painful rash on the external skin, but it is a significantly more severe disease than just a skin rash.

Two drugs, Tecovirimat and Brincidofovir were approved by the US FDA for Smallpox and MPox on the basis of the US FDA “Animal Rule,” i.e. based on animal infection and treatment studies only to demonstrate efficacy, and a safety/tolerability human clinical trial.

Tecovirimat failed in clinical trials for the treatment of MPox with no improvement over the standard of care. Brincidofovir was abandoned in a clinical trial of MPox due to first three patients coming down with drug induced liver injury. Despite this, brincidofovir was recently resurrected under an international coalition led by US CDC and first patient was dosed around January 2025 in the “MOSA” clinical trial ^[2] . The topline results were expected to be announced as early as CY Q1 (March 2025) and efficacy topline data were expected no later than CY Q2 (June, 2025). No press releases post initiation of the MOSA clinical trial could be found.

The MPox virus circulating in DRC and neighboring regions is of Clade 1a and Clade 1b subtypes, with the latter predominant. Clade 1b is more transmissible of the two, which is why it has resulted in a sustained epidemic. The MPox Clade 1a case fatality rate (CFR) is about 3%-11% whereas the CFR for Clade 1b is about 1%. The MPox Clade 2b is the virus causing continuing cases in the Western world, which causes a much less severe disease than Clade 1a/1b and has a very low CFR, according to CDC. Sporadic cases of Clade 1 in the Western world continue to occur. Four separate travel-related MPox Clade 1 cases reported in the USA that did not result in any further spread, since November 2024, according to the CDC ^[3] .

Clearly, the threat of MPox Clade 1 causing a potential epidemic in the USA cannot be ignored, and readiness with a drug that works against the same is important to achieve.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

View the original press release on ACCESS Newswire

• EIA Revisions to Address Concerns and Provide Pathway to Approval Without Resubmission of the Full EIA

• Key Environmental Improvements are being incorporated in the Ongoing Optimized Feasibility Study

TORONTO, ONTARIO / ACCESS Newswire / July 14, 2025 / Cerrado Gold Inc. (“Cerrado Gold” or the “Company”) is pleased to announce that its Portuguese subsidiary, Redcorp – Empreendimentos Mineiros, Lda. (“Redcorp”), has received notification from the Portuguese Environment Agency (Agência Portuguesa do Ambiente, “APA”) confirming that it will permit application of Article 16 procedures that allows Redcorp to submit revised technical documentation and project improvements to address APA comments, in relation to its Environmental Impact Statement (EIA) as outlined below.

Under Portuguese environmental law, Article 16 of the EIA Legal Framework allows developers to revise and resubmit elements of a previously submitted project in order to address identified environmental concerns, without restarting the full permitting process. This mechanism is designed to improve project outcomes while maintaining regulatory integrity and efficiency (Decreto-Lei n.º 151-B/2013, Diário da República, 1.ª série – N.º 211, de 31 de outubro de 2013).

The Company’s Optimized Feasibility Study (“OFS”), which is well underway, has proactively contemplated the changes requested, which are aimed at further strengthening the environmental and operational robustness of the proposed mining operation. In addition, the Company is continuing with all other activities as planned, such as detailed engineering alongside the work related to the OFS to minimize any impact on the overall development schedule while the Article 16 requirements are in process.

While application of Article 16(2) does not constitute project approval, it is a formal step under Portuguese law that enables developers to address concerns raised during the initial review and implement modifications, avoiding a full resubmission or rejection of the project. If the revised submission is accepted, the Company anticipates a final Environmental Impact Statement (EIA) decision could be issued in Q1 2026.

APA’s formal response follows Redcorp’s request, made during the public consultation and hearing period, to initiate the procedure foreseen in Article 16(2). In its reply, APA confirmed that, based on the justification provided by Redcorp, there are no objections to applying the Article 16(2) procedure. The Company now has 180 calendar days from the date of the notification to submit the revised project elements and a synthesis report addressing the required components outlined in the legal framework.

The Company’s revised submission will incorporate environmental and design improvements, including:

• Elimination of cyanide use across all processing stages at Lagoa Salgada, replaced by flotation-only circuits that has been validated through recent metallurgical testing;

• Enhanced protection of local aquifers and water resources, with new hydrogeological and geochemical control measures;

• Presentation of alternative borehole locations to support regional emergency water supply resilience;

• Deployment of a real-time environmental monitoring system, covering air, water, vibration, and noise parameters; and

• Application of Best Available Techniques (BAT) across the plant layout and mine design, improving performance and minimizing impact.

Mark Brennan, CEO and Chairman of Cerrado Gold, commented: “This is a constructive step forward for the Lagoa Salgada Project and demonstrates APA’s openness to a robust and transparent permitting process. We appreciate the opportunity to address concerns through technical and environmental improvements, which are seen as a typical request at this stage of the approval process. We note that many of the points raised by APA are already being integrated into the updated feasibility study due in September.”

Mr. Brennan continued: “With strong support from our stakeholders, including EDM, we remain confident that the revised submission will meet the highest standards of environmental compliance and will position the project for successful approval with minimal delay. Cerrado reiterates its strong commitment to developing the Lagoa Salgada Project as a model of environmental and technical excellence, delivering value to local communities, stakeholders, and European critical raw materials supply chains.”

The Company is further supported by its strategic partner in the project, EDM – Empresa de Desenvolvimento Mineiro, S.A. (“EDM”), a Portuguese state-owned mining development entity, with decades of experience in environmental remediation and mine water management. EDM has reaffirmed the strategic importance of the Lagoa Salgada Project to Portugal’s mining sector and expressed full confidence in the project’s ability to meet the highest environmental and operational standards.

Review of Technical Information

The scientific and technical information in this press release has been reviewed and approved by Andrew Croal, P.Eng., Chief Technical Officer for Cerrado Gold, who is a Qualified Person as defined in National Instrument 43-101.

About Cerrado

Cerrado Gold is a Toronto-based gold production, development, and exploration company. The Company is the 100% owner of the producing Minera Don Nicolás and Las Calandrias mine in Santa Cruz province, Argentina. In Portugal, the Company holds an 80% interest in the highly prospective Lagoa Salgada VMS project through its position in Redcorp – Empreendimentos Mineiros, Lda. In Canada, Cerrado Gold is developing its 100% owned Mont Sorcier Iron project located outside of Chibougamou, Quebec.

In Argentina, Cerrado is maximizing asset value at its Minera Don Nicolas (“MDN”) operation through continued operational optimization and is growing production through its operations at the Las Calandrias heap leach project. An extensive campaign of exploration is ongoing to further unlock potential resources in our highly prospective land package in the heart of the Deseado Masiff.

In Portugal, Cerrado is focused on the development and exploration of the highly prospective Lagoa Salgada VMS project located on the prolific Iberian Pyrite Belt in Portugal. The Lagoa Salgada project is a high-grade polymetallic project, demonstrating a typical mineralization endowment of zinc, copper, lead, tin, silver, and gold. Extensive exploration upside potential lies both near deposit and at prospective step-out targets across the large 7,209-hectare property concession. Located just 80km from Lisbon and surrounded by exceptional infrastructure, Lagoa Salgada offers a low-cost entry to a significant development and exploration opportunity, already showing its mineable scale and cashflow generation potential.

In Canada, Cerrado holds a 100% interest in the Mont Sorcier high-purity high-grade DRI Iron project, which has the potential to produce a premium iron concentrate over a long mine life at low operating costs and low capital intensity. Furthermore, its high-grade and high-purity product facilitates the migration of steel producers from blast furnaces to electric arc furnaces, contributing to the decarbonization of the industry and the achievement of sustainable development goals.

For more information about Cerrado please visit our website at: www.cerradogold.com.

Mark Brennan
CEO and Chairman

Mike McAllister
Vice President, Investor Relations
Tel: +1-647-805-5662
mmcallister@cerradogold.com

Disclaimer

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains statements that constitute “forward-looking information” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

Forward-looking statements contained in this press release include, without limitation, statements regarding the business and operations of Cerrado and its subsidiaries. Although the Company believes that it will receive a favourable EIA decision, no assurance can be provided. In making the forward- looking statements contained in this press release, Cerrado has made certain assumptions. Although Cerrado believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, Cerrado disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

SOURCE: Cerrado Gold Inc.

View the original press release on ACCESS Newswire

TAMPA, FLORIDA / ACCESS Newswire / July 14, 2025 / LUXE Cleaning Services®, a trusted name in residential and commercial cleaning throughout the Tampa Bay area, has been recognized with the 2025 Consumer Choice Award in the Janitorial Services category for Tampa. This honor highlights the company’s dedication to dependable, detailed, and customer-focused cleaning solutions that go beyond the ordinary.

Founded on the belief that great service starts and ends with people; LUXE Cleaning Services is known for its team of carefully selected professionals who deliver spotless results with a friendly, respectful touch. From sparkling homes to pristine office spaces, the company tailors each cleaning plan to fit the unique needs of its clients.

Cleaning with Care and Consistency
LUXE Cleaning Services offers a wide range of cleaning options, including routine residential cleanings, deep cleans, move-in and move-out services, and comprehensive janitorial solutions for commercial spaces. Every service is designed to help clients enjoy a cleaner, healthier, and more welcoming environment-without lifting a finger.

“We believe in raising the standard for what a cleaning service can be,” said the LUXE Cleaning Services team. “Receiving the Consumer Choice Award means so much to us because it reflects the trust and satisfaction of the community we proudly serve.”

People-First Approach, Exceptional Results
LUXE stands out for its commitment to hiring and training a team that embodies professionalism, reliability, and genuine care for clients’ spaces. By investing in high-quality cleaning products, detailed checklists, and responsive communication, LUXE ensures every visit leaves a noticeable difference.

Whether working in a family home, a busy office, or a newly renovated space, the team treats every property with the same attention to detail they’d expect in their own homes.

Serving Tampa Bay with Pride
As a locally owned business, LUXE Cleaning Services is deeply connected to the Tampa Bay community. The company actively supports local families and businesses by creating jobs, fostering trust, and giving clients the freedom to focus on what matters most.

Shaping What’s Next
With this recognition, LUXE Cleaning Services plans to expand its reach to more individuals, families, and businesses around Tampa Bay and invest in a more robust employer sponsored benefits package (adding to the paid time off, 401k with company match, and monthly therapeutic massage vouchers that they currently offer) to include medical, dental, vision benefits, and more. This will help them attract and retain only the most dedicated and detail-oriented professionals – making it easier than ever for Tampa Bay residents and businesses to maintain clean, healthy spaces for the years to come in partnership with LUXE.

To close, LUXE Cleaning Services is a company that values not only its client’s experience, but also the dignified and distinct employment position it provides for the proud members of its team.

To explore services, request a free quote, or book an appointment, CLICK HERE or visit www.luxetampabay.com.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

Following expanded 2,882m RC drilling program (results pending)

HIGHLIGHTS

• Tolmer high-grade silver discovery: expedited soil geochemistry program completed over ~1.9km² area surrounding recently expanded reverse circulation (RC) drilling program¹

ADELAIDE, AUSTRALIA / ACCESS Newswire / July 13, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) is pleased to confirm that an expedited soil sampling program has been completed over a ~1.9km² area surrounding the new ‘Tolmer’ high grade silver discovery at the Company’s South Australian Tarcoola Gold Project (Tarcoola). ~380 samples have been collected with assay results expected during September 2025.¹

¹ Refer to ASX announcements dated 10 and 16 June 2025

Commenting on the geochemical program, Barton Managing Director Alexander Scanlon said:

“We recently expanded our Tolmer ‘silver zone’ drilling by ~50% to cover a ~400 metre by ~250 metre area based, in part, upon further geological surface reconnaissance. This program extends that reconnaissance to a broader area of ~1,700 metres by ~1,100 metres to see if we can potentially identify a larger mineralised footprint.”

Program background

Barton identified Tolmer as a high-grade gold discovery in August 2024, and subsequently identified a new ‘silver zone’ ~500m west in a line of seven discovery holes with globally significant assays including 6m @ 4,747 g/t Ag from 46m, 14m @ 434 g/t Ag from 46m and 4m @ 1,417 g/t Ag from 9m.²

2,882m RC drilling was completed during June 2025 to test extensions of mineralisation in all directions, with the current geochemical sampling intended to potentially map a broader surface footprint.³

² Refer to ASX announcements dated 27 August 2024 and 30 January, 6 February, 27 March, 16 April, 22 May, 10 and 16 June 2025
³ Refer to ASX announcement dated 16 June 2025

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

Alexander Scanlon Managing Director a.scanlon@bartongold.com.au +61 425 226 649

Jade Cook Company Secretary cosec@bartongold.com.au +61 8 9322 1587

About Barton Gold

Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 1.9Moz Au & 3.1Moz Ag JORC Mineral Resources (73.0Mt @ 0.79 g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

Challenger Gold Project 223koz Au JORC Mineral Resources Region’s only gold processing plant (650ktpa CIP) Tarcoola Gold Project Fully permitted open pit mine with ~20koz Au within trucking distance of Barton’s Central Gawler Mill Historical goldfield with new high-grade gold-silver discovery in grades up to 83.6 g/t Au and 17,600 g/t Ag Tunkillia Gold Project 1.6Moz Au & 3.1Moz Ag JORC Mineral Resources Optimised Scoping Study for competitive ~120kozpa gold and ~250kozpa silver bulk open pit operation

Competent Persons Statement & Previously Reported Information

The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

Activity	Competent Person	Membership	Status
Tarcoola Mineral Resource (Stockpiles)	Dr Andrew Fowler (Consultant)	AusIMM	Member
Tarcoola Mineral Resource (Perseverance Mine)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Tarcoola Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tarcoola Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tunkillia Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information

This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

*Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 30 June 2025. Total Barton JORC (2012) Mineral Resources include 1,031koz Au (39.3Mt @ 0.82 g/t Au) in Indicated category and 834koz Au (33.8Mt @ 0.77 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

View the original press release on ACCESS Newswire